The shares of IDEXX Laboratories (NASDAQ: IDXX) experienced a sharp pre-market rise of 9.41 percent, increasing from the previous trading day’s close of $535.54 to $585.95. This significant surge was driven by the company’s impressive Q2 2025 financial results, which exceeded expectations.
IDEXX’s revenue for the quarter was reported at $1.11 billion, surpassing the estimated $1.06 billion. Similarly, its adjusted earnings of $3.50 per share beat the estimate of $3.28. This represents an 11% increase in revenue and a 15.9% rise in adjusted earnings from the same quarter in the previous year.
